LUNG CANCER MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)
Segmentation
By TypeNon-Small Cell Lung Cancer (NSCLC) (Adenocarcinoma, Squamous Cell Carcinoma, and Large Cell Carcinoma) · Small Cell Lung Cancer (SCLC) · and Lung Carcinoid Tumor
By Drug ClassCytotoxic Chemotherapy (Alkylating agents (cisplatin, carboplatin, etc.), Antimetabolites (pemetrexed, gemcitabine), Mitotic inhibitors (taxanes: paclitaxel, docetaxel), Topoisomerase inhibitors (etoposide, irinotecan), and Others) · Targeted Therapy (EGFR Inhibitors (Erlotinib, etc.), ALK Inhibitors (Crizotinib, etc.), ROS1 Inhibitors (Entrectinib, etc.), BRAF/MEK Inhibitors (Dabrafenib, etc.), MET Inhibitors (Capmatinib, etc.), RET Inhibitors (Selpercatinib, etc.), HER2 Inhibitors (Trastuzumab, etc.)) · Immunotherapy · (PD-1 Inhibitors (Nivolumab, etc.), PD-L1 Inhibitors (Atezolizumab, etc.), CTLA-4 Inhibitors (Ipilimumab, etc.)) · and Other Combination Therapeutics) and Other Combination Therapeutics
By Molecule TypeSmall Molecules and Biologics
By Route of AdministrationParenteral and Oral
By Stage of DiseaseEarly-stage (Stage I–II) · Locally Advanced (Stage III) · and Metastatic/Advanced (Stage IV)
By Age GroupAdult · Pediatric · and Geriatric
By GenderMale and Female
By Distribution ChannelHospital Pharmacies · Retail Pharmacies · and Online Pharmacies
By End UserHospitals · Diagnostic Laboratories · Specialty Cancer Clinics · Homecare Settings · and Others (Research and Academic Institutes, etc.)
By GeographyNorth America · Europe · Asia Pacific · Latin America · Middle East · and Africa
Published In10 Mar 2026
Report CodeCMI8494
Pages250+
FormatsExcel and PDF
Base Year2025
Estimated Year2026
Historical Range2020 - 2024
Forecast Period2026-2033
Market Segmentation
Type Insights (Revenue, USD Bn, 2021 - 2033)
Non-Small Cell Lung Cancer (NSCLC)
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Small Cell Lung Cancer (SCLC)
Lung Carcinoid Tumor
Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
